Vertex Pharmaceuticals Inc.’s acquisition of Alpine Immune Sciences Inc. makes strategic sense and will bolster the company’s rare-disease franchise, analysts said Thursday.
Vertex Pharma’s $4.9 billion takeover of Alpine Immune expected to boost its rare-disease portfolio
